IP Library Granted Patent US 10,220,212
Granted Patent B2
US 10,220,212 · App. 15/395,872 · Granted Mar 5, 2019

Neurostimulation titration process

Inventors: Imad Libbus (St. Paul, MN); Bruce H. Kenknight (Maple Grove, MN); Badri Amurthur (Los Gatos, CA)
Assignee: LivaNova USA, Inc.
A61N1/36157A61B5/0205A61B5/0245A61B5/4836A61N1/36114A61N1/36132A61N1/36139A61N1/36171A61N1/36175A61B5/02055
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,220,212
App. No.
15/395,872
Granted
Mar 5, 2019
Kind
B2
Abstract

Systems and methods are provided for delivering neurostimulation therapies to patients for treating chronic heart failure. A titration process is used to gradually increase the stimulation intensity to a desired therapeutic level. This titration process can minimize the amount of time required to complete titration so as to begin delivery of the stimulation at therapeutically desirable levels.

Claims (39)

1. A neurostimulation system, comprising:

an electrode assembly;

a neurostimulator coupled to the electrode assembly, the neurostimulator adapted to deliver a stimulation signal to a patient;

a physiological sensor configured to acquire a physiological signal from the patient; and

a processor coupled to the neurostimulator and the physiological sensor, the processor being configured to:

at an initial titration session, activate the neurostimulator to deliver the stimulation signal with an initial stimulation parameter set, the initial parameter set comprising an output current, a frequency, a pulse width, and a duty cycle;

perform a titration process, the titration process comprising:

increasing the output current of the stimulation signal until the stimulation signal comprises a target output current or adequate adaption is achieved, wherein adequate adaptation comprises at least one of a side effect level below a side effect tolerance zone boundary, a target physiological response or a target parameter set;

after increasing the output current of the stimulation signal, in response to the patient exceeding the side effect tolerance zone boundary before the stimulation signal comprises the target output current, decreasing the frequency and subsequently increasing the output current until either the stimulation signal comprises the target output current or the patient again exceeds the side effect tolerance zone boundary; and

after the stimulation signal comprises the target output current, increasing at least one of the frequency, the pulse width or the duty cycle while maintaining the target output current until a composite threshold is reached, wherein the composite threshold is reached when the stimulation signal comprises the target parameter set or the patient exceeds the side effect tolerance zone boundary.

2. The neurostimulation system of claim 1 , wherein the target parameter set comprises a target frequency of between 8 Hz and 12 Hz.

3. The neurostimulation system of claim 1 , wherein subsequently increasing the output current comprises maintaining the frequency, the pulse width and the duty cycle of the stimulation signal.

4. The neurostimulation system of claim 1 , wherein decreasing the frequency and subsequently increasing the output current comprises decreasing the frequency to about 5 Hz or less.

5. The neurostimulation system of claim 1 , wherein the titration process further comprises:

after decreasing the frequency to a lowered frequency level and subsequently increasing the output current, in response to the patient again exceeding the side effect tolerance zone boundary before the stimulation signal comprises the target output current while at the lowered frequency level, increasing the frequency to an elevated frequency level and subsequently increasing the duty cycle until either the stimulation signal comprises a target duty cycle or the patent subsequently exceeds the side effect tolerance zone boundary.

6. The neurostimulation system of claim 1 , wherein decreasing the frequency and subsequently increasing the output current the further comprises after increasing the output current of the stimulation signal, in response to the patient exceeding the side effect tolerance zone boundary before the stimulation signal comprises the target output current, decreasing the frequency and the pulse width and subsequently increasing the output current until either the stimulation signal comprises the target output current or the patient again exceeds the side effect tolerance zone boundary.

7. The neurostimulation system of claim 1 , wherein the processor is further configured to:

determine a physiological response to the stimulation signal by:

monitoring a baseline signal acquired by the physiological sensor during OFF time periods of the stimulation signal; and

monitoring a response signal acquired by the physiological sensor during ON time periods of the stimulation signal.

8. A neurostimulation system, comprising:

an electrode assembly;

a neurostimulator coupled to the electrode assembly, the neurostimulator adapted to deliver a stimulation signal to a patient;

a physiological sensor configured to acquire a physiological signal from the patient; and

a processor coupled to the neurostimulator and the physiological sensor, the processor configured to:

at an initial titration session, activate the neurostimulator to deliver the stimulation signal with an initial stimulation parameter set, the initial parameter set comprising an output current, a frequency, a pulse width, and a duty cycle;

perform a titration process, the titration process comprising:

increasing the output current of the stimulation signal until the stimulation signal comprises a target output current;

after increasing the output current of the stimulation signal, in response to the patient exceeding a side effect tolerance zone boundary before the stimulation signal comprises the target output current, decreasing the frequency and subsequently increasing the output current until either the stimulation signal comprises the target output current or the patient again exceeds the side effect tolerance zone boundary; and

after the stimulation signal comprises the target output current, increasing at least one of the frequency, the pulse width or the duty cycle while maintaining the target output current.

9. The neurostimulation system of claim 8 , wherein subsequently increasing the output current comprises maintaining the frequency, the pulse width and the duty cycle of the stimulation signal.

10. The neurostimulation system of claim 8 , wherein decreasing the frequency and subsequently increasing the output current comprises decreasing the frequency to about 5 Hz or less.

11. The neurostimulation system of claim 8 , wherein the titration process further comprises:

after decreasing the frequency to a lowered frequency level and subsequently increasing the output current, in response to the patient again exceeding the side effect tolerance zone boundary before the stimulation signal comprises the target output current while at the lowered frequency level, increasing the frequency to an elevated frequency level and subsequently increasing the duty cycle until either the stimulation signal comprises a target duty cycle or the patent subsequently exceeds the side effect tolerance zone boundary.

12. The neurostimulation system of claim 8 , wherein decreasing the frequency and subsequently increasing the output current further comprises after increasing the output current of the stimulation signal, in response to the patient exceeding the side effect tolerance zone boundary before the stimulation signal comprises the target output current, decreasing the frequency and the pulse width and subsequently increasing the output current until either the stimulation signal comprises the target output current or the patient again exceeds the side effect tolerance zone boundary.

13. The neurostimulation system of claim 8 , wherein the processor is further configured to:

determine a physiological response to the stimulation signal by:

monitoring a baseline signal acquired by the physiological sensor during OFF time periods of the stimulation signal; and

monitoring a response signal acquired by the physiological sensor during ON time periods of the stimulation signal.

Assignments (7)
RELEASE OF SECURITY INTEREST Recorded Sep 20, 2021
From: ACF FINCO I LP
To: LIVANOVA USA, INC.
Reel/Frame 057552/0378 →
SECURITY INTEREST Recorded Aug 16, 2021
From: LIVANOVA USA, INC.
To: GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT
Reel/Frame 057188/0001 →
RELEASE OF SECURITY INTEREST Recorded Aug 16, 2021
From: ARES CAPITAL CORPORATION, AS AGENT FOR THE LENDERS
To: LIVANOVA USA, INC.
Reel/Frame 057189/0001 →
PATENT SECURITY AGREEMENT Recorded Dec 30, 2020
From: LIVANOVA USA, INC.
To: ACF FINCO I LP, AS COLLATERAL AGENT
Reel/Frame 054881/0784 →
PATENT SECURITY AGREEMENT Recorded Jun 17, 2020
From: LIVANOVA USA, INC.
To: ARES CAPITAL CORPORATION, AS COLLATERAL AGENT
Reel/Frame 053673/0675 →
CHANGE OF NAME Recorded Jan 16, 2019
From: CYBERONICS, INC.
To: LIVANOVA USA, INC.
Reel/Frame 048078/0257 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 24, 2017
From: LIBBUS, IMAD; KENKNIGHT, BRUCE H.; AMURTHUR, BADRI
To: CYBERONICS, INC.
Reel/Frame 041369/0820 →
Continuity (2)
Continuation 14457807 · Aug 12, 2014
Related Publication 20170106194A1 · Apr 20, 2017